Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered app aims to predict Alzheimer's years before symptoms worsen

NCT ID NCT07731191

Knowledge-focused Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study is testing whether a smartphone app can help predict the risk of developing Alzheimer's disease. Researchers will collect health data like weight, blood pressure, and blood sugar from people with mild cognitive concerns. An artificial intelligence model will analyze these risk factors to see if it can identify who is most likely to develop dementia. The goal is to create a tool that could one day allow for earlier, more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a mobile app for risk monitoring and patient engagement
What this could lead to
If successful, this could lead to a simple, non-invasive way to identify people at high risk for Alzheimer's disease before symptoms worsen.
What could go wrong
This is an early-stage study focused on building and testing a prediction model, not a treatment. The app's risk assessment may not be accurate enough for real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects aged more than 18 years at the time of signing the informed consent form; * Subjects with MCI or SCD who, at the time of their first visit, did not have a clinical diagnosis of dementia (MMSE ≥ 24); * Smartphone user. Exclusion Criteria: * Age younger than that stated in the inclusion criterion; * Inability to understand.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment (MCI) Subjective cognitive decline (SCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ASST Spedali Civili di Brescia

    RECRUITING

    Brescia, BS, 25123, Italy

  • IRCCS Istituto Centro San Giovanni Di Dio - Fatebenefratelli

    RECRUITING

    Brescia, BS, 25125, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.